HOME


PAST DIGITAL ISSUES


HIV/AIDS HOTLINES


HIV 101


POSITIVE PROFILES


ASO SPOTLIGHT


RECENT ARTICLES


HOW TO PAY FOR HIV TREATMENT AND MEDICATIONS


ADAP CRITERIA AND FORMULARIES


ASO LISTINGS


REVIEW OF HIV MEDICATIONS


2017 HIV/AIDS FUNDRAISING ACTIVITIES & EVENTS


ABOUT HIV POSITIVE! MAGAZINE


LINKS


SUBSCRIBE


CONTACT US


ADVERTISER INFORMATION

Fusion Inhibitor

This class of drug is meant to interfere with the entry, fusion or binding of the HIV virus to a healthy cell.


FUZEON

(Enfuvirtide)

DHHS Status: Not Recommended

Manufacturer: Genentech (www.gene.com)
Fuzeon (www.fuzeon.com)

FDA approval date: March 13, 2003

Financial Assistance: https://www.gene.com/patients/medicines/fuzeon

The standard dose of Fuzeon is 90mg, which is injected into the upper arm, thigh or abdomen after being reconstituted, or mixed with sterile water, twice a day.
It’s important to rotate the injection site with each dose.

Review: Fuzeon was a “salvage drug” and was first approved by the FDA back in 2003 as a second chance for those who had developed resistance to other HIV drugs. Since then many newer, more effective, cheaper and MUCH more convenient drugs have entered the market. Fuzeon is rarely prescribed anymore.


Single Tablet Regimens

Protease Inhibitors

Nucleoside Reverse Transcriptase Inhibitors

Non-Nucleoside Reverse Transcriptase Inhibitors

Fusion Inhibitor

Entry Inhibitor

Integrase Inhibitor

Pharmacokinetic Enhancer


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 




Copyright 2017, Positive Health Publications, Inc.

This magazine is intended to enhance your relationship with your doctor - not replace it! Medical treatments and products should always be discussed with a licensed physician who has experience treating HIV and AIDS!